Exploring mesoporous silica nanoparticles as oral insulin carriers: <i>In-silico</i> and <i>in vivo</i> evaluation.

Heliyon · 2023 · PMC10556789 · PMID 37810809

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Additionally, the body weights of the treated groups (including MSN and insulin) showed a trend of weight gain, while the STZ group showed a trend of weight loss ( Fig. 4 C).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.